Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology and EMBLEM Collaborate to Streamline Drug Development

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
Initiative strengthens drug development and commercialization network.

MRC Technology has announced that it has entered into a strategic collaboration with EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), the exclusive technology transfer partner of the European Molecular Biology Laboratory (EMBL).

The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics.

The agreement brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.

Dr Dave Tapolczay, MRC Technology’s CEO, commented, “Heidelberg is a world centre for academic research and we are delighted to be collaborating with EMBLEM, and researchers from the EMBL Chemical Biology group. The skills of the two organizations are highly complementary, and the initiative further strengthens MRC Technology’s academic drug development and commercialization network - ultimately working towards improving the rate at which academic research is translated into new medicines.”

EMBLEM’s Managing Director, Dr. Gábor Lamm, said “We work closely with a network of partners to develop technologies to a sufficient level of maturity such that they can be transferred to industry. We look forward to working with MRC Technology to identify projects for collaborative screening and further development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Drug Royalties Monetised
MRC Technology monetises royalties on cancer drug Keytruda (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital.
Monday, July 18, 2016
MRC Technology Appoints Two New Members to Board of Trustees
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
Thursday, April 07, 2016
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
MRC Technology Appoints General Counsel and Company Secretary
Dr Edward Bliss will join MRCT on 16 March.
Wednesday, February 04, 2015
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases.
Tuesday, July 22, 2014
UCB and UK’s MRC Technology Sign Exclusive License Agreement
UCB to develop an antibody-based therapy for the treatment of fibrotic disease.
Friday, February 14, 2014
MRC Technology and Boston University Collaborate to Develop anti-IL-16 Antibody
Cytokine IL-16 implicated in inflammation and Ischaemic Reperfusion Injury.
Friday, October 11, 2013
MRC Technology and Arthritis Research UK Launch Joint ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of musculoskeletal conditions.
Tuesday, September 03, 2013
MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
Antibody inhibits tumour angiogenesis, migration and invasion.
Wednesday, March 20, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!